I alpha-hydroxycholecalciferol: a treatment of renal bone disease.
Three patients with chronic renal failure on maintenance haemodialysis have been treated with 1 alpha-hydroxycholecalciferol (1 alpha-OHCC), a synthetic vitamin D analogue. A daily dose of 2 mug by mouth produced a significant increase in both calcium absorption from the gastrointestinal tract and calcium content of bone. Treatment with 1 alpha-OHCC appears to be effective in cases of metabolic bone disease associated with chronic renal failure.
D000284:Administration, Oral; D000328:Adult; D001847:Bone Diseases / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D002128:Calcium Metabolism Disorders / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D006887:Hydroxycholecalciferols / Q000008:administration & dosage / Q000627:therapeutic use*; D007275:Injections, Intravenous; D007408:Intestinal Absorption / Q000187:drug effects; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D006887:Hydroxycholecalciferols; D002118:Calcium